Evidence map›Paper›PMID 40463244›Full record

ArticlebioRxiv : the preprint server for biology2025

Gut microbial conversion of dietary elderberry extract to hydrocinnamic acid improves obesity-associated metabolic disorders.

Sara Alqudah, Beckey DeLucia, Lucas J Osborn, Rachel L Markley, Viharika Bobba, Sarah M Preston, Tharika Thambidurai, Layan Hamidi Nia, Clifton G Fulmer, Naseer Sangwan and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sara AlqudahDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Beckey DeLuciaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Lucas J OsbornDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Rachel L MarkleyDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Viharika BobbaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Sarah M PrestonDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Tharika ThambiduraiDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Layan Hamidi NiaDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Clifton G FulmerDepartment of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute of the Cleveland Clinic; Cleveland, OH, USA.
Naseer SangwanDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Ina NemetDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.
Jan ClaesenDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute of the Cleveland Clinic; Cleveland, OH, USA.ORCID 0000-0002-0755-7974

Funding

Uncovering aryl polyene biology to identify new drug targets in Gram-negative bacterial pathogensR01AI153173 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI CLAESEN, JAN · 2021 to 2025
$2.0M
NIAID NIH HHS R01 AI153173
6 · The paper itself

Abstract

Obesity-associated metabolic disorders such as type 2 diabetes mellitus and metabolic dysfunction associated fatty liver disease are major global health concerns, yet current pharmacological treatments often present with major side-effects. Dietary interventions including polyphenol-rich foods offer a promising complementary option for obesity amelioration, but their efficacy is dependent on specific gut microbial metabolism and the underlying molecular mechanisms mostly remain elusive. Here, we demonstrated that dietary elderberry (Eld) extract abrogates the effects of an obesogenic diet in a gut microbiota-dependent manner, by preventing insulin resistance and reducing hepatic steatosis in mice. We developed a targeted, quantitative liquid chromatography-tandem mass spectrometry method for detection of gut bacterial polyphenol catabolites and identified hydrocinnamic acid as a key microbial metabolite, enriched in the portal vein plasma of Eld supplemented animals. Next, we showed that hydrocinnamic acid potently activates hepatic AMP-activated protein kinase α, explaining its role in improved liver lipid homeostasis. Furthermore, we uncovered the metabolic pathway cumulating in hydrocinnamic acid production in the common gut commensal

Indexed as

gut microbiomehepatic steatosishydrocinnamic acidinsulin resistanceMAFLDobesitytype 2 diabetes

Identifiers

PMID40463244
PMCPMC12132264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.